These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6554517)

  • 1. Parkinson's disease.
    Holt P
    Nursing (Lond); 1983 Jul; 2(15):448-50. PubMed ID: 6554517
    [No Abstract]   [Full Text] [Related]  

  • 2. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Professional development. Parkinson's disease. Revision notes.
    Stewart N
    Nurs Times; 1996 Jan 17-23; 92(3):9-12; quiz 13-4. PubMed ID: 8577614
    [No Abstract]   [Full Text] [Related]  

  • 4. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of selegiline as initial monotherapy in early Parkinson's disease.
    Bhatia M; Jain S; Maheshwari MC
    J Assoc Physicians India; 1994 Jan; 42(1):30-2. PubMed ID: 7836244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Professional development. Parkinson's disease. The role of the nurse.
    Nurs Times; 1996 Jan 10-6; 92(2):5-8 suppl. PubMed ID: 8577593
    [No Abstract]   [Full Text] [Related]  

  • 9. [Which drug to use for the initiation of treatment for early Parkinson's disease].
    Marttila R
    Duodecim; 2004; 120(5):587-90. PubMed ID: 15060995
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
    Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of Parkinson's disease].
    Villette N; Marsault M
    Soins; 1980 Oct; 25(19):39-41. PubMed ID: 6910141
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term follow-up of globus pallidus chronic stimulation in advanced Parkinson's disease.
    Durif F; Lemaire JJ; Debilly B; Dordain G
    Mov Disord; 2002 Jul; 17(4):803-7. PubMed ID: 12210880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.
    van Hilten JJ; van der Zwan AD; Zwinderman AH; Roos RA
    Mov Disord; 1994 Jan; 9(1):84-8. PubMed ID: 8139609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa therapy for Parkinson's disease: challenges and future prospects.
    Olanow CW; Lees A; Obeso J
    Mov Disord; 2008; 23 Suppl 3():S495-6. PubMed ID: 18781670
    [No Abstract]   [Full Text] [Related]  

  • 16. [Disturbance of micturition in Parkinson's disease].
    Sakakibara R; Uchiyama T; Yoshiyama M; Hattori T
    No To Shinkei; 2001 Nov; 53(11):1009-14. PubMed ID: 11761908
    [No Abstract]   [Full Text] [Related]  

  • 17. [Analysis of the nursing factors responsible for expanding the sphere of daily activities of patients with Parkinson's disease].
    Ota S; Nagasaki K; Baba M; Ninamihira Y
    Sogo Kango; 1989 May; 24(2):95-114. PubMed ID: 2612141
    [No Abstract]   [Full Text] [Related]  

  • 18. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease.
    Hauser RA; Holford NH
    Mov Disord; 2002 Sep; 17(5):961-8. PubMed ID: 12360545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
    Antonini A; Mancini F; Canesi M; Zangaglia R; Isaias IU; Manfredi L; Pacchetti C; Zibetti M; Natuzzi F; Lopiano L; Nappi G; Pezzoli G
    Neurodegener Dis; 2008; 5(3-4):244-6. PubMed ID: 18322402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
    Bermejo Pareja F; Martínez-Martín P
    Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.